Compare HSBC Holdings plc (HSBC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Moderna, Inc. — how do they compare? HSBC Holdings plc trades at $104 (market cap $353.82B), while Moderna, Inc. trades at $63.65 (market cap $24.18B). The key difference: HSBC Holdings plc is far larger — about 14.6× Moderna, Inc.'s market cap, and HSBC Holdings plc pays a 3.63% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| HSBC | MRNA | |
|---|---|---|
Market Cap | $353.82B | $24.18B |
Sector | Technology | Health |
52-Week High | $107.86 | $81.80 |
52-Week Low | $63.84 | $22.36 |
Dividend Yield | 3.63% | — |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $104.12, up 0.77% today, with a bullish technical signal from moving averages and support near $103. The bank reported strong Q2 2026 results with a 7% revenue increase and a $1 billion buyback, while net income margin improved to 34.54% in 2026. Analyst sentiment is mixed, with 38.1% buy ratings, but recent news includes a Citi downgrade citing a 40% stock run-up.
The outlook remains positive due to earnings momentum and shareholder returns, but risks include China regulatory changes and valuation concerns after the recent rally. Further upside depends on sustained revenue growth and effective capital allocation.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
